Pharmaceutical procurement among public sector procurers in CARICOM
Rev Panam Salud Publica
; 45, may 2021
Article
in English
| PAHO-IRIS
| ID: phr-53910
Responsible library:
US1.1
ABSTRACT
[ABSTRACT]. Objective. To examine multiple aspects of the medicines in CARICOM procurement markets, including manufacturer headquarters location, regulatory history, and type (innovator versus generic); the proportion of World Health Organization (WHO) essential medicines; and the most expensive medicines procured. Methods. An analysis of procurement information from selected CARICOM procurers. Four public sector procurement lists were obtained based on public availability or sharing of data from public sector procurers. Analyses were based on parameters available or deduced from these data. Results. The majority of products come from manufacturers headquartered in North America and Europe (63%–67%). The percentage of medicines procured from generic companies is 60%–87%; and 25%–50% of medicines procured are on the WHO Essential Medicines List. Wide price variations exist in the most expensive medicines purchased. Conclusions. The analysis identifies vulnerabilities and opportunities in the procurement situation of CARICOM states, particularly related to quality and rational use of medicines. This analysis represents a baseline that governments and other stakeholders can use in the future.
Full text:
Available
Collection:
Databases of international organizations
Health context:
Sustainable Health Agenda for the Americas
/
SDG3 - Health and Well-Being
Health problem:
Goal 5: Medicines, vaccines and health technologies
/
Target 3.8 Achieve universal access to health
Database:
PAHO-IRIS
Main subject:
Economics, Pharmaceutical
/
Caribbean Region
/
Drug Industry
/
Pharmaceutical Trade
/
Access to Essential Medicines and Health Technologies
Type of study:
Health economic evaluation
/
Prognostic study
Language:
English
Year:
2021
Document type:
Article